drugset / Trial / NCT00058240

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

NCT00058240

Phase 1/2 Completed 52 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of flavopiridol in treating patients with previously treated chronic lymphocytic leukemia or lymphocytic lymphoma. Drugs used in chemotherapy such as flavopiridol work in different ways to stop cancer cells from dividing so they stop growing or die.

Timeline

Start
2003-04
Primary completion
2009-02
Completion
2009-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule 80 mg/m2 Intravenous